Sunday, June 30, 2013

Toshiba Introduces Motor Driver IC Realizing Zero Current[1] in Standby Mode

TOKYO - Friday, June 28th 2013 [ME NewsWire]

Toshiba Corporation (TOKYO: 6502) today announced it has launched a full-bridge DC motor driver IC, "TB67H301FTG", for use in consumer and industrial equipment, including printers, vending machines and amusement machines. Mass production starts today. The IC incorporates a standby function that realizes zero power supply current[1] in standby mode. It adopts a small, leadless WQFN24 package that reduces the mounting area to 1/3 that of equivalent products, contributing the downsizing of the equipment and the reduction of PCB cost.

Features

1. Built-in power saving function Newly integrated shutdown circuit cuts current to zero[1] in standby mode.

2. Small package The WQFN24 package has good thermal conductivity and realizes the same absolute maximum ratings[2] for voltage and current value as equivalent products. The small and leadless package reduces the mounting area.

3. Built-in abnormality detection function TB67H301FTG incorporates an overcurrent shutdown circuit, undervoltage lockout circuit and thermal shutdown circuit.
           

Key Specifications

Product name
         

TB67H301FTG

Absolute maximum ratings[2] (Power supply voltage: Output current)
         

40V/6V: 3.0A

Power supply voltage (Operating ranges)
         

Power supply voltage for motor: 4.5V to 38V

Power supply voltage for control: 3.0V to 5.5V

Other features
         

Forward/Reverse/Short brake/Stop

PWM control

PWM constant-current control

Standby function

Over current shutdown circuit

Undervoltage lockout circuit

Thermal shutdown circuit

Package
         

WQFN24 (4.0mm×4.0mm×0.75mm)
           

Notes: [1] Power supply current in standby mode: 0.1μA or less. [2] The stress level which may cause permanent damages to the device if it is exceeded.

Customer Inquiries: Mixed Signal Controller Group Tel: +81-44-548-2821


Information in this document, including product prices and specifications, content of services and contact information, is current on the date of the announcement but is subject to change without prior notice.


About Toshiba

Toshiba is a world-leading diversified manufacturer, solutions provider and marketer of advanced electronic and electrical products and systems. Toshiba Group brings innovation and imagination to a wide range of businesses: digital products, including LCD TVs, notebook PCs, retail solutions and MFPs; electronic devices, including semiconductors, storage products and materials; industrial and social infrastructure systems, including power generation systems, smart community solutions, medical systems and escalators & elevators; and home appliances.

Toshiba was founded in 1875, and today operates a global network of more than 550 consolidated companies, with 202,000 employees worldwide and annual sales surpassing 6.1 trillion yen (US$74 billion). Visit Toshiba's web site at www.toshiba.co.jp/index.htm

Photos/Multimedia Gallery Available:  http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50661680&lang=en

Contacts
Media Inquiries:
Toshiba Corporation
Semiconductor & Storage Products Company
Takashi Mochizuki, +81-3-3457-4963
semicon-NR-mailbox@ml.toshiba.co.jp

Saturday, June 29, 2013

Delta Faucet Celebrates Five Years of Leadership in Touch and Hands-Free Technologies

Delta Faucet spotlights its Touch2O® Technology at showrooms globally

INDIANAPOLIS - Saturday, June 29th 2013 [ME NewsWire]

(BUSINESS WIRE)-- Delta Faucet Company has been at the forefront in research and design of touch and hands-free faucet technologies in the home for more than a decade. Since 2008 when the Delta® brand introduced Touch2O® Technology, the first faucet technology of its kind, Delta Faucet has continued to enhance the way consumers interact with their kitchen and bath faucets. In recognition of this five-year milestone, hundreds of showrooms across the globe now demonstrate the wide breadth of Delta kitchen and bath faucets with Touch2O and Touch2O.xt™ Technologies.

“As a global leader in kitchen and bath innovation, we’ve seen our Touch2O® and Touch2O.xt™ Technologies continue to grow in popularity among consumers by improving their experience and helping to make their interactions near the sink more convenient for the whole family,” said Catherine Roper, director of Delta® brand management. “We’re excited to celebrate this important milestone at showrooms where customers and consumers can connect with our brand and learn more about what makes Delta touch technologies unique.”

Delta Touch2O Technology is based on highly responsive, precise and reliable capacitance sensing technology, similar to that found on smart phones, tablets and other touch-activated devices. Unlike with infrared sensors, outside factors such as lighting conditions, color and highly reflective objects do not interfere with capacitance sensing capability.

Through its research, Delta Faucet found that while certain tasks may benefit from hands-free functionality, the majority of people gravitate to the control and responsiveness of touch activation in the kitchen. Touch2O Technology affords consumers the ability to precisely control the activation of water exactly when and where it’s needed - even when hands are full or messy. With Touch2O Technology, users can simply tap anywhere on the spout, hub or handle of the faucet to turn the water stream on or off. Water temperature and volume is adjusted easily above the deck using the faucet handle.

In 2011, Touch2O Technology was introduced on lavatory faucets and was expanded to include Touch2O.xt Technology, providing the option of hands-free functionality in the bathroom, where proximity sensing was found to be desired. Today, five kitchen suites and three bathroom suites feature Touch Technologies in international markets. These offerings address three unique style categories – genuine, versatile or modern – to fit different style preferences. The Delta brand’s award-winning Touch Technologies also have been recognized globally for innovation and design, including the Edison Awards, ADEX Awards, Green Product Awards, American Business “Stevie” Awards and Building Products magazine MVP Awards.

Globally, Delta Touch2O Technology can be experienced through working displays in:

    The United States with hundreds of showrooms, including the company’s flagship Dream2O® Showroom
    Canada with more than 150 showrooms
    Brazil with more than 50 showrooms and at the Brazil Expo Revestir, which took place March 2013
    India with three showrooms
    China with five showrooms and at the May 2013 Kitchen and Bath China exhibition
    The Middle East with five showrooms
    Asia with five showrooms
    Mexico with five showrooms
    Latin America with more than 20 showrooms
    The Caribbean with eight showrooms

About Delta® Products

There is a philosophy at the heart of every Delta® product: there is a better way to live with water. It goes beyond excellent design to incorporate smart thinking that anticipates people's needs. From proprietary Touch2O® Technology that turns faucets on and off with just a touch to H2Okinetic® shower technology that sculpts water into a unique wave pattern, giving you the feeling of more water without using more water, Delta products incorporate thoughtful features that delight. Paired with beautiful and inspirational design, the Delta® brand is more than just a faucet. A WaterSense® partner of the U.S. Environmental Protection Agency, Delta Faucet Company is a global organization that offers kitchen faucets, bath faucets, shower heads, shower systems, toilets and related accessories, selling products in more than 53 countries. For more information, visit worldwide.deltafaucet.com.

Links to additional resources

Delta Touch2O Technology

Delta Online Press Room

Contacts

Media Contact:

MSL Chicago

Katie Feltz, 312-861-5256

katie.feltz@mslgroup.com

Toshiba Launches New Power Amplifier IC for Car Audio


Reduces sound cuts and noise of car audio at engine idle reduction

TOKYO - Thursday, June 27th 2013 [ME NewsWire]

(BUSINESS WIRE)-- Toshiba Corporation (TOKYO:6502) today announced that it has launched a 4 channel power amplifier IC, "TB2941HQ", that improves noise tolerance in audio systems in cars with engine idling reduction systems. Samples are available now with mass production scheduled to start in July 2013. Engines of cars with idling reduction systems often cut out, causing battery voltage to drop. By reducing the minimum operation voltage from 8V to 6V, the new power amplifier realizes stable operation and makes it possible to prevent the loss of sound and noise in car audio. This IC improves noise tolerance with a newly developed filter circuit, and minimizes the influence of cellular phone waves on the sound. Reinforced protection circuits realize high reliability.


Specifications

Part Number
         

TB2941HQ

Maximum Output Power
         

49W x 4ch (VCC=15.2V, RL=4Ω, JEITA max) 70W x 4ch (VCC=14.4V, RL=2Ω, JEITA max)

Operating Supply Voltage Range
         

6V~18V

Total Harmonic Distortion
         

0.006% (POUT=4W)

Output Noise Voltage
         

55uV (BW=DIN_AUDIO)

Embedded Functions and Features
         

    High output power and low distortion
    Built in mute and standby functions, offset detection, and high side switch driver
    6V operations (Engine idling reduction capability)
    Variety of protection circuits (thermal, overvoltage, output to VCC, output to GND, output to output protections, cross misconnection, VCC shorted to output when set-GND is opened, GND shorted to output when set-VCC is opened)

Package
         

HZIP25-P-1.00F

Sample Price (Tax included)
         

500 Yen
           

Customer Inquiries:         Mixed Signal Controller Group Tel: +81-44-548-2821


Information in this document, including product prices and specifications, content of services and contact information, is current on the date of the announcement but is subject to change without prior notice.


About Toshiba Toshiba is a world-leading diversified manufacturer, solutions provider and marketer of advanced electronic and electrical products and systems. Toshiba Group brings innovation and imagination to a wide range of businesses: digital products, including LCD TVs, notebook PCs, retail solutions and MFPs; electronic devices, including semiconductors, storage products and materials; industrial and social infrastructure systems, including power generation systems, smart community solutions, medical systems and escalators & elevators; and home appliances.

Toshiba was founded in 1875, and today operates a global network of more than 550 consolidated companies, with 202,000 employees worldwide and annual sales surpassing 6.1 trillion yen (US$74 billion). Visit Toshiba's web site at www.toshiba.co.jp/index.htm

Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20130627005535/en/

Contacts

Media Inquiries:

Toshiba Corporation

Semiconductor & Storage Products Company

Takashi Mochizuki, +81-3-3457-4963

semicon-NR-mailbox@ml.toshiba.co.jp









Permalink: http://me-newswire.net/news/7806/en

Hilton Worldwide and Vital Voices Global Partnership Launch Global Freedom Exchange, a Collaboration to End Child Trafficking

New Program to Strengthen the Capacity of Women NGO Leaders in Fight Against Trafficking

MCLEAN, Va. - Thursday, June 27th 2013 [ME NewsWire]

(BUSINESS WIRE)-- Today, Hilton Worldwide and Vital Voices Global Partnership announced that they have joined forces to help end child trafficking. Together, they have launched the Global Freedom Exchange, an innovative, multi-faceted educational and mentoring program targeting emerging and established women leaders. Program participants are on the forefront of global efforts to prevent and respond to the crime of child trafficking. Global Freedom Exchange is intended to create an international network of activists.

As a fundamental element of the Global Freedom Exchange, Hilton Worldwide and Vital Voices have brought together a select group of 26 women leaders from 13 countries, to participate in a two-week interactive learning and networking program. This event spans three U.S. cities - areas that have strong national and international resources focused on addressing human trafficking – Washington, DC, New York City, and Dallas, Texas. Activities include opportunities to meet with government officials and NGO leaders to provide donors with knowledge about funding and other support needs and to learn about collaborating with local law enforcement.

“Hilton Worldwide takes an aggressive stance against child trafficking, and we continually seek innovative partnerships that will enable us to make a real difference on such an important issue,” explained Kristin Campbell, EVP and general counsel, Hilton Worldwide. “We are very proud to support Vital Voices and invest in the crucial efforts of these amazing women. We believe that each can make a vast and deep impact, and we are fully committed to helping them realize their full leadership potential.”

Program participants are established or emerging leaders recognized for their passion and commitment to ending human trafficking and their innovative approach to this global issue. They include founders, advisors, legal counsels and program managers from non-governmental organizations. The women come from:

    Ethiopia
    India
    Macau
    Mexico
    Panama
    Peru
    Philippines
    Poland
    Russia
    South Africa
    Thailand
    Turkey
    United States

“The goal of this program is to provide participants with specific knowledge, skills and relationships that will benefit their professional development, their respective NGOs and the communities they serve,” explained Alyse Nelson, president and CEO of Vital Voices Global Partnership. “The program will also develop an ongoing international network of activists working together to prevent and respond to the scourge of child sex trafficking throughout the world.”

This multi-year partnership between Hilton Worldwide and Vital Voices is part of Travel with Purpose™, Hilton Worldwide’s promise to providing shared value to its business and communities around the globe. It is an extension of the organization’s existing work to address child trafficking worldwide. Hilton Worldwide is the second U.S. multi-brand hospitality company to sign the ECPAT Code of Conduct and is signatory of the UN Global Compact. In addition to child trafficking awareness and training programs for hotel employees, the company also supports the capacity of non-governmental organizations to increase their programs to reach trafficking survivors.

Together, Hilton Worldwide and Vital Voices will provide a network of support, connecting each participant with Hilton Worldwide hotels in their communities to explore partnerships that will enhance their on-the-ground work. Five $10,000 grants will be awarded to the most collaborative and innovative projects addressing the Global Freedom Exchange’s mission to end child trafficking worldwide. Participants will also become members of the Vital Voices Global Leadership Network, which includes over 14,000 innovative change agents in more than 140 countries.

For more information about the Global Freedom Exchange and to learn more about program participants, visit http://www.vitalvoices.org/blog/2013/06/global-freedom-exchange-working-end-child-sex-trafficking.

About Hilton Worldwide

Hilton Worldwide is a leading global hospitality company, spanning the lodging sector from luxurious full-service hotels and resorts to extended-stay suites and mid-priced hotels. For 94 years, Hilton Worldwide has offered business and leisure travellers the finest in accommodations, service, amenities and value. The company is dedicated to continuing its tradition of providing exceptional guest experiences across its global brands. Its brands are comprised of more than 3,900 hotels and timeshare properties, with 650,000 rooms in 90 countries and territories and include Waldorf Astoria Hotels & Resorts, Conrad Hotels & Resorts, Hilton Hotels & Resorts, DoubleTree by Hilton, Embassy Suites Hotels, Hilton Garden Inn, Hampton Hotels, Homewood Suites by Hilton, Home2 Suites by Hilton and Hilton Grand Vacations. The company also manages the world-class guest reward program Hilton HHonors®. Visit www.hiltonworldwide.com for more information and connect with Hilton Worldwide at www.facebook.com/hiltonworldwide, www.twitter.com/hiltonworldwide, www.youtube.com/hiltonworldwide, www.flickr.com/hiltonworldwide and www.linkedin.com/company/hilton-worldwide.

About Vital Voices Global Partnership

Vital Voices Global Partnership is a leading non-governmental organization that identifies, invests in and brings visibility to remarkable women around the world by unleashing their leadership potential to transform lives and accelerate peace and prosperity in their communities. Founded by U.S. Secretary of State Hillary Clinton in 1997, the organization trains and mentors women leaders as agents of transformative change in economic development, human rights and political participation. The Vital Voices Global Leadership Network includes more than 14,000 leaders representing 144 countries who have trained and mentored 500,000 additional women and girls in their communities. Visit www.vitalvoices.org to learn more.

Contacts

Astrid Egerton-Vernon, Hilton Worldwide

703 883 5696

Astrid.Egerton-Vernon@hilton.com



or

Margaux Bergen

Vital Voices Global Partnership

202.333.1928

MargauxBergen@vitalvoices.org



 

Friday, June 28, 2013

Gemalto Wins “Best LTE Security Product” Award

LinqUs™ Advanced over-the-Air Platform + UpTeq™ UICC Card = Security, Identity, Mobility

        
AMSTERDAM - Thursday, June 27th 2013 [ME NewsWire]

(BUSINESS WIRE)-- Gemalto (Euronext NL0000400653 GTO), the world leader in digital security, has won the “Best LTE Security Product Award” at the LTE World Summit 2013. The award recognizes the best-in-class security delivered by Gemalto’s Advanced Connectivity solution, which combines the LinqUs™ Advanced OTA platform with the UpTeq™ LTE UICC card. This end-to-end solution creates a fast and secure connectivity layer, on top of which mobile operators and service providers can deploy new value added services such as LTE subscription activation, payment applications, multimedia distribution and machine-to-machine (M2M) connectivity.

Telecom operators, service providers and end-users everywhere share the same concern for clear protection of sensitive credentials. Gemalto’s core business is founded on over 20 years of experience in security processes, cryptography, embedded software and connecting platforms. This expertise spans the entire process of creating digital security solutions that inspire the trust of customers and found in billions of trusted devices that the company delivers annually.

This prestigious industry prize is the fifth secured by Gemalto’s Advanced Connectivity solution in the span of just two years. Building on the company’s LinqUs™ Advanced OTA platform and UpTeq™ LTE UICC card, Gemalto’s Advanced Connectivity solution provides robust security, reliability and ease-of-use for both mobile network operators and end users. It creates a secure channel for exchanges between the LTE SIM application located in the UICC card and the Advanced OTA platform, utilizing end-to-end encryption. Once in place, this secure channel can be used by Gemalto’s Allynis Trusted Service Manager and other application management platforms for fast and secure service delivery.

Constantly tested against the latest industry standards, the Advanced Connectivity solution is designed to offer high speed, low latency, and help ensure a 100% success rate when activating, updating or managing advanced services. Over 15 leading clients worldwide have already put their trust in the unrivaled level of security delivered by this industry-leading technology.

“LTE + UICC = Security, Identity, Mobility,” commented Philippe Vallée, Executive Vice President at Gemalto. “With our dedicated expertise in security and commitment to mobility, Gemalto is perfectly positioned in the sweet spot where these two key drivers meet. The Advanced Connectivity solution allows mobile operators to leverage the high bandwidth of LTE to deliver a range of secure services to their customers.”

About Gemalto

Gemalto (Euronext NL0000400653 GTO) is the world leader in digital security with 2012 annual revenues of €2.2 billion and more than 10,000 employees operating out of 83 offices and 13 Research & Development centers, located in 43 countries.

We are at the heart of the rapidly evolving digital society. Billions of people worldwide increasingly want the freedom to communicate, travel, shop, bank, entertain and work – anytime, everywhere – in ways that are enjoyable and safe. Gemalto delivers on their expanding needs for personal mobile services, payment security, authenticated cloud access, identity and privacy protection, eHealthcare and eGovernment efficiency, convenient ticketing and dependable machine-to-machine (M2M) applications. We develop secure embedded software and secure products which we design and personalize. Our platforms and services manage these products, the confidential data they contain and the trusted end-user services made possible.

Our innovations enable our clients to offer trusted and convenient digital services to billions of individuals. Gemalto thrives with the growing number of people using its solutions to interact with the digital and wireless world.

For more information visit www.gemalto.com, www.justaskgemalto.com, blog.gemalto.com, or follow @gemalto on Twitter.

Contacts

Gemalto

Media

Peggy Edoire, +33 4 42 36 45 40

Europe, Middle East & Africa

peggy.edoire@gemalto.com



or

Pierre Lelievre, +65 6317 3802

Asia Pacific

pierre.lelievre@gemalto.com



or

Nicole Smith, +1 512 758 8921

North America

nicole.smith@gemalto.com



or

Ernesto Haikewitsch, +55 11 5105 9220

Latin America

ernesto.haikewitsch@gemalto.com



Permalink: http://www.me-newswire.net/news/7799/en

Thursday, June 27, 2013

Sumitomo Selects QUAKE’s Q4000 M2M Device for Its Next Generation Telematics Solution

Q4000 empowers Sumitomo to gain competitive advantage in the Heavy Equipment Industry

SAN DIEGO - Wednesday, June 26th 2013 [ME NewsWire]

(BUSINESS WIRE)-- Quake Global, Inc., a leading manufacturer of M2M (machine-to-machine) devices for satellite and terrestrial networks, announced that Sumitomo Construction Machinery Co., Ltd. will integrate QUAKE’s Q4000 to further enhance and optimize its telematics solutions. The Q4000 is a rugged M2M hardware and software platform designed to accelerate time-to-market while reducing sustaining costs over M2M product life cycles.

Sumitomo, a leading manufacturer of excavators, asphalt pavers and other construction equipment, is a long-standing customer of QUAKE, having pioneered the integration of QUAKE’s Q1200 modem into its equipment tracking and monitoring telematics solution in 2005. Sumitomo’s decision to upgrade to QUAKE’s new generation Q4000 consolidates various hardware components onto one state-of-the-art hardware platform, thus, optimizing the total cost of its next generation telematics solution. Furthermore, the Q4000 introduces other new capabilities such as automatically routing data through the most-efficient wireless network and CANBUS integration.

“QUAKE and Sumitomo have been close technology partners for many years, and we look forward to continuing our relationship with this industry leader. Sumitomo’s decision to extend their relationship with QUAKE by adopting our new technology reinforces QUAKE’s long-standing position as the leader in heavy equipment telematics,” stated Polina Braunstein, QUAKE’s President & CEO. “Our products are designed so that customers like Sumitomo can concentrate on maximizing their product development and production efforts while QUAKE concentrates on reducing Sumitomo’s burden of managing the complex M2M technology environment.”

About Quake Global, Inc.:

QUAKE™ designs and manufactures industrial M2M modules for asset tracking and monitoring through satellite, cellular, GPS and other technologies. Through a network of international distributors, QUAKE products serve OEMs and other companies in the heavy equipment, aviation, maritime, and trucking industries, as well as in utility, oil & gas, and rail applications. QUAKE is proud to provide high-quality subscriber communicators for BELL EQUIPMENT, CATERPILLAR, FARIA, HITACHI, HYUNDAI, KOMATSU, MARINE INSTRUMENTS, SUMITOMO, VOLVO, and many others. For more information, visit www.quakeglobal.com.

Contacts
Quake Global, Inc.
Sandi Harrison
858-277-7290, Ext. 287

Luxoft Holding, Inc Announces Pricing of Initial Public Offering

TORTOLA, British Virgin Islands - Wednesday, June 26th 2013 [ME NewsWire]

(BUSINESS WIRE)-- Luxoft Holding, Inc announced today the pricing of its initial public offering of 4,092,070 Class A ordinary shares at $17.00 per Class A ordinary share. Luxoft’s Class A ordinary shares are expected to begin trading on the New York Stock Exchange under the symbol “LXFT” on June 26, 2013.

Luxoft is offering 2,046,035 Class A ordinary shares, and another 2,046,035 Class A ordinary shares are being offered by its parent, IBS Group Holding Limited. The underwriters have been granted a 30-day over-allotment option to purchase up to 613,810 additional Class A ordinary shares from the selling shareholder to cover over-allotments, if any. The offering is expected to close on July 1, 2013.

UBS Limited, Credit Suisse Securities (USA) LLC, J.P. Morgan Securities LLC, VTB Capital plc and Cowen and Company, LLC are the joint bookrunning managers for the offering. A copy of the final prospectus related to the offering may be obtained when available from UBS Securities LLC, by telephone at 1-888-827-7275 or by mail at Attention: Prospectus Department, 299 Park Avenue, New York, NY 10171; from Credit Suisse Securities (USA) LLC, by telephone at 1-800-221-1037, by mail at Attention: Prospectus Department, One Madison Avenue, New York, NY 10010, or by email at newyork.prospectus@credit-suisse.com; from J.P. Morgan Securities LLC, by telephone at 1-866-803-9204 or by mail at Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717; from VTB Capital plc by telephone at +1 646-527-6313 or by mail at 452 Fifth Avenue, 23rd Floor, New York NY 10018; or from Cowen and Company, LLC, by telephone at 1-631-274-2806 or by mail at Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717.

A registration statement relating to these securities has been deemed effective by the United States Securities and Exchange Commission. This press release does not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Luxoft

Luxoft is a leading provider of software development services and innovative IT solutions to a global client base consisting primarily of large multinational corporations. Luxoft’s software development services consist of core and mission critical custom software development and support, product engineering and testing, and technology consulting. Luxoft’s solutions are based on its proprietary products and platforms that directly impact its clients’ business outcomes and efficiently deliver continuous innovation.

Contacts

Media

Luxoft

Alina V. Plaia, 201-245-8086

VP, Head of Analyst Relations

APlaia@luxoft.com

GE Healthcare and Konica Minolta agree to collaborate on a DR retrofit global distribution agreement, enhancing strategic alliance

MILWAUKEE - Thursday, June 27th 2013 [ME NewsWire]

(BUSINESS WIRE)-- GE Healthcare (NYSE: GE) and Konica Minolta Inc. have signed a global distribution agreement(*) of Konica Minolta’s AeroDR cassette-size digital x-ray imaging retrofit. Having built a collaborative relationship for nearly ten years related to the sales of computed radiography (CR)1 in the United States, the two partners have now agreed to expand their strategic alliance, with GE Healthcare distributing AeroDR not just within the United States, but globally as well, using GE Healthcare sales channels.

The AeroDR, introduced as the world’s lightest, most compact wireless-type cassette digital x-ray device of its kind, is already in use in a wide range of medical workplaces, contributing the advantages of high image quality at low x-ray dose2 comparing to CR. The agreement will enable healthcare facilities that have x-ray analog devices to implement digital imaging upgrades using their current imaging equipment. In addition, a selection of three cassette sizes adds versatility: 10”x12” 3, 14”x17” and 17”x17”.

The agreement adds the AeroDR panel to the GE Healthcare lineup of digital x-ray devices, thus enabling both partners to accelerate their supply of solutions adapted to the needs of a diverse array of customers. Building on the solutions to meet a broad range of customer needs globally the alliance contributes to innovation in healthcare.

(*) except in Japan.

Sales by GE Healthcare are underway using a global sales network and will progressively be spanning over 50 countries.

Notes:

1. As opposed to the use of x-ray film in conventional systems, an imaging plate (IP) records the x-ray image data, which is then converted into a visual image by a reading device.

2. The irradiated dose is received by a sensor panel, directly acquiring the image digitally, and thus providing superior image quality, as well as shorter imaging times.

3. Work in Progress in some countries

About Konica Minolta

With MFPs (multi-functional peripherals) and other office equipment at the core of its business activities, Konica Minolta also provides products and services to meet the industrial needs of society for production materials and equipment, healthcare, planetariums, and more. In the healthcare field, Konica Minolta has been a pioneer of analog x-ray film in Japan, and now provides a wide range of products and services to meet the needs of the healthcare workplace, centering diagnostic medical imaging technologies. In recent years, Konica Minolta has been providing total IT services and hardware systems that contribute to the progress of the healthcare field as it becomes ever more digitized and networked. In this way, Konica Minolta contributes to more rapid, reliable diagnostic services.

About GE Healthcare

GE Healthcare provides transformational medical technologies and services to meet the demand for increased access, enhanced quality and more affordable healthcare around the world. GE (NYSE: GE) works on things that matter - great people and technologies taking on tough challenges. From medical imaging, software & IT, patient monitoring and diagnostics to drug discovery, biopharmaceutical manufacturing technologies and performance improvement solutions, GE Healthcare helps medical professionals deliver great healthcare to their patients.

Contacts

GE Healthcare

Pilar Anton Serrano

Global Communications Manager, Detection & Guidance Solutions (DGS)

+33665874751

pilar.antonserrano@ge.com



or

Konica Minolta Medical Imaging USA Inc.

Dianne B. Servidio-Magella

Channel Marketing Manager

1.800.934.1034 Extension 1342

dservidio@mi.konicaminolta.us






GE Healthcare Survey Shows People Don’t Associate Bad Habits with Breast Cancer

Family support more influential than public health campaigns and celebrity diets when trying to kick bad habits and lead a healthier lifestyle

CHALFONT ST. GILES, England - Thursday, June 27th 2013 [ME NewsWire]

(BUSINESS WIRE)-- New research commissioned by GE Healthcare, undertaken by TNS in eight countries1 last month, has revealed that adults are unaware of the link between bad habits such as smoking, excessive alcohol consumption or physical inactivity and breast cancer.

While respondents to the survey were well aware of the relationship between bad habits and the possible risk of developing lung, liver and colon cancer, the awareness of the link to breast cancer was comparatively low: between 28% (in Germany) and 60% (in China) (see chart 1).

The survey revealed that the main reason people find it tough to break bad habits was addiction. However, the second most cited reason by respondents was a lack of information and knowledge, suggesting that while public awareness campaigns for lung, liver and colon cancer do a good job of informing the general public about the risks of bad habits, more work could be done to highlight the link to breast cancer.

When respondents were asked about their personal monitoring routines and how often people should check their bodies for unusual bumps and growths some startling disparities appeared (see chart two).

    33% of British, 42% of Americans and alarmingly 93% of Japanese and 86% of Chinese respondents said they do not check their body at least one a month
    In other countries, the percentage of people not checking themselves once a month hovered between 50% and 80%
    Unsurprisingly, women are more conscientious than men at checking their bodies each month

The survey also revealed that families are the most important source of influence, motivation and inspiration for those wanting to lead a healthier lifestyle. At least 70% of respondents in each country said that they would look to their family for support.

Doctors and other medical professionals are another main source of advice and influence for those surveyed and were cited as the second most influential group. However, while French respondents are most likely to heed advice from their healthcare professionals over their family, Chinese respondents were less likely to value the advice of healthcare professionals.

Faring much worse in the survey were both government health campaigns and celebrities promoting a certain lifestyle or diet. With the exception of Brazil and Turkey, celebrities had minimal influence in those countries looking for advice on how to lead a healthy lifestyle.

- ends -

A pdf of the research findings can be downloaded at: http://newsroom.gehealthcare.com/articles/lack-of-awareness-between-bad-habits-and-breast-cancer.

Editor’s Notes

1 TNS conducted the survey on behalf of GE Healthcare and polled over 1,000 adults between May 31 and June 5 in Brazil (adults 16-54), China (adults 16-44), France (adults 16-64), Germany (adults 16-64), Japan (adults 16-64), Turkey (adults 16-54), Great Britain (adults 16-64) and the United States (adults 18-64).

GE Healthcare’s #GetFit 2013 campaign (www.ge-getfit.com) runs until mid-July and leverages social media channels including Instagram, Sina Weibo in China, and Twitter to enable participation, interaction and engagement of a global audience to promote healthy habits that can help reduce the likelihood of developing cancer.

About GE Healthcare

GE Healthcare provides transformational medical technologies and services to meet the demand for increased access, enhanced quality and more affordable healthcare around the world. GE (NYSE:GE) works on things that matter - great people and technologies taking on tough challenges. From medical imaging, software & IT, patient monitoring and diagnostics to drug discovery, biopharmaceutical manufacturing technologies and performance improvement solutions, GE Healthcare helps medical professionals deliver great healthcare to their patients. For our latest news, please visit http://newsroom.gehealthcare.com

In September 2011, GE Healthcare announced it would dedicate $1 billion of its total R&D budget over the next five years to expand its advanced cancer diagnostic and molecular imaging capabilities, as well as its world-class technologies for the manufacture of biopharmaceuticals and for cancer research.

Contacts

GE Healthcare

Allison Cohen

PR and Communications Manager

+972 (0)54-7299-742

allison.cohen@ge.com



Will Spiers

Global PR Director

+44 1494 545278/ +44 7971 276757

william.spiers@ge.com



 

Wednesday, June 26, 2013

A2iA Mobility™ Released for iOS Devices, Expanding its Reach within the Worldwide Mobile Document Capture and Data Recognition Markets

A2iA Mobility delivers next-generation offline recognition capabilities required for real-time business operations, and organizations looking to expand their existing mobile solutions in emerging markets.


PARIS & NEW YORK - Wednesday, June 26th 2013 [ME NewsWire]

(BUSINESS WIRE)-- A2iA (@A2iA), a trusted name in the Worldwide data capture, document processing, and payment systems markets, announced today the availability of A2iA Mobility™ for iOS devices, expanding its reach to include both the Android and iOS platforms. Since its launch earlier this year, A2iA Mobility, a patent-pending software toolkit that delivers all image cleanup, analysis and data extraction functionality to the local device for offline recognition, has seen an increase in activity around the world and is currently being deployed within mobile remote deposit capture (mRDC) applications at banks and credit unions.

“A2iA Mobility delivers next-generation capabilities for organizations looking to expand their existing mobile offerings across vertical markets and geographical territories” said Jean-Louis Fages, A2iA President and Chairman of the Board. “With a simpler user experience, room for customization and the ability to perform without a server or data connection, A2iA Mobility creates a smarter handset and delivers the required capabilities to meet real-time business operational demands.”

By leveraging A2iA’s award-winning R&D Team, A2iA Mobility’s Global footprint and capabilities can be expanded to address new versions as they relate to the country, industry or document-type. Applicable to a multitude of documents including checks, identification documents and other forms, A2iA Mobility is an API, customizable within the host application and easily interfaceable with existing banking software, such as internal risk management solutions. Users receive immediate confirmation that all identified data-points have been accurately captured prior to sending to the financial institution or back office, reducing manual re-keying and the number of times the data and image are transferred between parties, changing the way mobile data recognition takes place with a more seamless user experience.

About A2iA Mobility™

A2iA Mobility™ is a patent-pending software development kit (SDK) available in multiple country- and language-versions for integration into mobile data capture and recognition applications, such as mobile remote deposit capture. A robust software with the ability to perform all image cleanup and recognition on the native device, A2iA Mobility delivers application diversity by allowing users to broaden their mobile product offerings for applications such as account openings, bill pay, and payment processing.

About A2iA

A2iA, Artificial Intelligence and Image Analysis (www.a2ia.com), is the worldwide leading developer of handwritten and machine printed text recognition, information extraction and intelligent document classification toolkits. By enhancing solutions from systems integrators and independent software vendors, A2iA allows complex and cursive data from all forms, documents and checks including unstructured handwritten letters, to become part of a structured database, making it searchable and reportable, with the same level of flexibility of printed or digital data. Proven to reduce costs and nearly eliminate data-entry and manual document processing, A2iA has been improving business process automation and delivering a visible ROI for over 20 years. For more information, visit www.a2ia.com or call +1 917-237-0390 within the Americas, or +33 1 44 42 00 80 within EMEA or Asia.

Contacts

Media :

A2iA

Wendi A. Klein, +1-917-237-0390 x 4034

Director, Marketing & Business Development, North America

wendi.klein@a2ia.com



or

A2iA Corporation:

24 West 40th Street, 3rd Floor

New York, NY 10018 USA

+1.917.237.0390 office

+1.917.237.0391 fax






Tuesday, June 25, 2013

Oberthur Technologies’ NFC Embedded Secure Element Equips the Newly Released Samsung GALAXY S4

COLOMBES, France- June 25, 2013 -(BUSINESS WIRE/ME NewsWire)-- Oberthur Technologies, one of the world’s largest providers of security and identification solutions and services based on smart card technologies, today announced its selection by Samsung Electronics to provide PEARL, the state-of-the-art NFC embedded Secure Element (eSE) for the newly released GALAXY S4.

Oberthur Technologies’ PEARL is the most advanced multi-application embedded Secure Element and offers the largest memory on the market. It is also the first of its kind to be certified by Visa, MasterCard and Google. PEARL allows easy deployment of secure NFC payment, strong authentication, transit, access and loyalty applications.
Oberthur Technologies is a recognised leader in trusted payment and plays a key role in the ecosystem through supplying solutions and facilitating connections for a large number of financial institutions and service providers.

“We are proud to be recognised through this contract as a trusted partner for the deployment of secured NFC services in the Samsung GALAXY S4” said Cédric Collomb, Telecom Business Unit Managing Director at Oberthur Technologies. “Teams have collaborated very closely to deliver the best-in-class secured eSE NFC services for this long-awaited smartphone”.
Oberthur Technologies offers OEMs its NFC security expertise along with certified NFC applications, the TSMs to manage them dynamically, and benefits stemming from its relationships with an extended network of service providers.

About Oberthur Technologies

Oberthur Technologies is a world leader in the field of secure technologies: systems development, solutions and services for smart cards (payment cards, SIM cards, access cards, NFC…) and for secure identity documents, traditional and electronic (identity card, passport, health care card). Created in 1984, Oberthur Technologies employs over 6 000 employees. With 50 sales offices across 5 continents, Oberthur Technologies’ international network serves clients in 140 countries.

For more information: www.oberthur.com
*Source: ME NewsWire
The press release can be viewed online: http://www.me-newswire.net/news/7764/en

Contacts

Media Contacts
Oberthur Technologies
Annika Hellgren, Tel. : +33 6 03 07 23 87
Email : a.hellgren@oberthur.com
or
FTI Consulting
Yannick Duvergé, Tel.: +33 1 47 03 68 65 / +33 6 74 91 48 05
Email: yannick.duverge@fticonsulting.com

View this news release and multimedia online at:
http://www.businesswire.com/news/home/20130624005794/en

Big Data Pioneer Terapeak Launches New Analytics Solution for Amazon.com

Online Merchants Will Gain Insights and Visibility into the Amazon Marketplace

PALO ALTO, Calif. - Tuesday, June 25th 2013 [ME NewsWire]

(BUSINESS WIRE)-- Terapeak today announced the release of Terapeak for Amazon.com, a break-through E-commerce market analytics solution, designed to provide visibility into the Amazon marketplace. Online retailers will have access to Amazon market data as well as their own sales data, enabling them to compare key performance indicators.

Terapeak for Amazon.com features product, offer and sales rank searches in over 35 Amazon categories; average, minimum and maximum pricing data; competitor research and analysis, and the ability to view historical Amazon transactions. Online merchants can also analyze and measure product and sales performance across multiple channels. With Terapeak for Amazon.com, online sellers now have unique insight into the competitive environment that is the Amazon marketplace, and yet another Terapeak-powered way to build distance between themselves and their competitors.

"Terapeak has been renowned for its ability to provide marketplace visibility for eBay merchants, but with multi-channel selling becoming the new normal, our customers were asking us to deliver analytics for Amazon.com as well," said Kevin North, President & CEO of Terapeak. “Now, not only have we delivered it, but we have also integrated their own sales data into the application. By bringing all this knowledge together in one place, our customers will have even greater insights into the E-commerce landscape, and a superior understanding of their own relative position.”

Terapeak has always been a pioneer of Big Data analytics, launching its first online application, Terapeak for eBay, in 2004. Using proprietary analytics that cut through the complexity of ecommerce transactional data, Terapeak offers unique marketplace intelligence to clients ranging from small business merchants to Fortune 500 companies. E-commerce merchants use Terapeak’s reporting to evaluate sourcing opportunities, price points, market trends, product behavior across regions, and their competition. Terapeak analyzes over 2.4 billion transactions per year and over $68 Billion in online consumer spending worldwide. Terapeak offers a free seven-day trial of its full subscription package – which includes Terapeak for eBay, Terapeak for Amazon, and Terapeak MySales – on its website at Terapeak.com.

Visit Terapeak’s website: www.terapeak.com

Like Terapeak on Facebook: https://www.facebook.com/Terapeak

Follow Terapeak on Twitter: https://twitter.com/Terapeak

About Terapeak

Terapeak is the leading source for analyzing, understanding and predicting consumer and product behavior in e-commerce. As the first authorized analytics provider of eBay market data, and the leading aggregator of e-commerce data for eBay, Amazon, Yahoo! Japan and Magento, Terapeak is an indispensable resource for over 1.3 million online merchants.

Contacts

Media Contact:
Terapeak
Shelley D'Amico, 250 661 5901
Director, Communications & Creative Services
sdamico@terapeak.com

Monday, June 24, 2013

The Estée Lauder Companies Appoints Philippe Warnery to General Manager, Canada

NEW YORK - Monday, June 24th 2013 [ME NewsWire]

(BUSINESS WIRE)-- Thia Breen, Group President, North America for The Estée Lauder Companies Inc. (NYSE: EL), announced that Philippe Warnery has been appointed to the position of General Manager, Canada.

Mr. Warnery will be responsible for the growth and profitability of the Canadian affiliate with a focus on locally relevant opportunities, assessing market conditions, building key account relationships, managing operational effectiveness, building capabilities, and aligning and engaging the Canada team. Mr. Warnery’s appointment is effective August 12, 2013 and he will report to Ms. Breen.

“Canada is an important strategic focus for the North America region and Philippe will be a key member of my leadership team. He has broad experience in developing and executing international marketing strategies and a collaborative style that will serve him well in this new role. I am delighted to welcome him to our team,” said Ms. Breen.

Mr. Warnery joined the The Estée Lauder Companies in 2006 and most recently served as the Vice President, General Manager, International for the Origins and Ojon brands. In this role, he spearheaded the successful expansion of Origins into China, Norway, Sweden, the Netherlands and most recently Mexico. Mr. Warnery has also been instrumental in the development of the expansion of Origins and Ojon with Boots in the UK.

Prior to his work with Origins and Ojon, Mr. Warnery served as the Regional Director for Clinique Travel Retail in APAC, where he positioned Clinique as a top five brand in over 20 key airports and duty free locations.

The Estée Lauder Companies Inc. is one of the world’s leading manufacturers and marketers of quality skin care, makeup, fragrance and hair care products. The Company’s products are sold in over 150 countries and territories under the following brand names: Estée Lauder, Aramis, Clinique, Prescriptives, Lab Series, Origins, M•A•C, Bobbi Brown, Tommy Hilfiger, Kiton, La Mer, Donna Karan, Aveda, Jo Malone, Bumble and bumble, Darphin, Michael Kors, American Beauty, Flirt!, GoodSkin Labs, Grassroots Research Labs, Tom Ford, Coach, Ojon, Smashbox, Ermenegildo Zegna, Aerin Beauty, Osiao and Marni.

Contacts

The Estée Lauder Companies Inc.

Media Relations:

Alexandra Trower, 212-572-4430

Application submitted to the European Medicines Agency (EMA) for use of Pradaxa® in treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and prevention of recurrent DVT and PE

INGELHEIM, Germany - Monday, June 24th 2013 [ME NewsWire]

    Data show Pradaxa® is as effective as the standard of care while offering safety advantages in the treatment of acute and the prevention of recurrent DVT and PE1,2,3
    Pradaxa® is already approved for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and for the primary prevention of venous thromboembolic events in patients undergoing elective total hip replacement or total knee replacement surgery4
    In-market experience with Pradaxa® already spans over 1.6 million patient-years in all currently licensed indications in over 100 countries worldwide5

(BUSINESS WIRE)-- For media outside of the U.S., the UK & Canada only

Boehringer Ingelheim today announced the submission of an application to the European Medicines Agency (EMA) for use of Pradaxa® (dabigatran etexilate) for the treatment of acute deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE.i

“Given the risk of potentially fatal consequences and recurrences of a deep vein thrombosis or pulmonary embolism, there is a need for safe and effective therapies to improve outcomes for patients,” said Professor Klaus Dugi, Corporate Senior Vice President Medicine, Boehringer Ingelheim. “Our studies have demonstrated that Pradaxa® offers an effective treatment with significant safety benefits compared to warfarin both for acute treatment as well as in the long-term prevention of recurrent events. We are convinced that this treatment option can provide benefits to patients with acute DVT or PE, or those at risk of recurrent DVT and PE.”

The EMA submission is based on the results of four global Phase III studies investigating the efficacy and safety of Pradaxa® in the treatment of acute DVT and PE and in secondary prevention of recurrent DVT and PE.1,2,3 In these studies, Pradaxa® was proven to be as effective as warfarin, with lower rates of clinically relevant bleeding (which includes major bleeding) and total bleeding for patients with DVT or PE.1,2,3 When compared to placebo, Pradaxa® prevented nine out of ten episodes of recurrent DVT and PE.1 The results of the RE-COVER®, RE-MEDY™ and RE-SONATE® studies have been published in the New England Journal of Medicine.1,2 All studies are part of the extensive RE-VOLUTION® clinical trial programme investigating Pradaxa® in multiple indications.

Pradaxa® is already widely approved for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and for the primary prevention of venous thromboembolic events in patients undergoing elective total hip replacement and total knee replacement surgery.4 In-market experience with Pradaxa® already spans over 1.6 million patient-years in all currently licensed indications in over 100 countries worldwide.5

Pradaxa® is currently not approved for the acute treatment or prevention of recurrent DVT and PE.

i Important Notice: Pradaxa® (dabigatran etexilate) is currently not approved for the acute treatment or prevention of recurrent deep vein thrombosis and pulmonary embolism

~ENDS~

Please click on the link below for ‘Notes to Editors’ and ‘References’:

http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2013/24_june_2013_dabigatranetexilate.html

Contacts

Boehringer Ingelheim GmbH

Sara McClelland

Corporate Communications

Media + PR

Phone: +49 6132 – 77 8271

E-mail: press@boehringer-ingelheim.com

Twitter: http://twitter.com/Boehringer

www.boehringer-ingelheim.com

Sunday, June 23, 2013

The Coca-Cola Foundation Gives Back $36 Million to Raise Living Standards Worldwide

Funding supports global efforts to strengthen communities, promote well-being, and protect our environment

ATLANTA - Saturday, June 22nd 2013 [ME NewsWire]

(BUSINESS WIRE)-- The Coca-Cola Foundation -- the global philanthropic arm of The Coca-Cola Company -- awarded US$36 million in grants to 105 community organizations during the first quarter of 2013. The grants support the Foundation’s global priority areas and the Company’s three-part sustainability approach, focused on enhancing people’s well-being, building strong communities and protecting the environment.

“Coca-Cola wants to be a positive force in communities around the world,” said Lisa M. Borders, Chair of The Coca-Cola Foundation and Vice President of Global Community Connections for The Coca-Cola Company. “Through these grants, we have an amazing opportunity to make a real difference for millions of people by supporting personal well-being programs, improving access to critical natural resources such as clean water and supporting many other sustainable community programs.”

During the first quarter 2013, The Foundation awarded:

    $12 million for physical activity and well-being programs;
    $12 million for water stewardship, recycling, and environmental programs; and
    $12 million for local priorities and social well-being programs, such as access to education opportunities, youth development, economic empowerment, HIV/AIDS and malaria prevention and other civic initiatives.

Those organizations receiving grant funding from The Coca-Cola Foundation during the first quarter of 2013 include:

WELL-BEING

Active Healthy Living

    American College Of Sports Medicine Foundation, Inc., Georgia Exercise Is Medicine Network, United States, $80,000
    American Friends of The University of Ulster, Sports for Life All Island, Europe, $350,000
    American University Of Beirut, Evidence-Based Nutrition Intervention Program, Eurasia and Africa, $90,000
    Amerihealth Mercy Foundation, Health Ministry Empowerment Tour, United States $25,000
    Beijing Normal University Education Foundation, Balanced Diet – Active Living, China, $400,000
    Camp Twin Lakes, Paddle Board Program and Camper Scholarships, United States, $30,000
    Catholic Charities Community Services, Archdiocese of New York, Youth Challenge, United States, $1.5 million
    Center for Health Policies and Services, Healthy Lifestyle Educational Project II, United States, $404,000
    Croatian Diabetes Association, Diaeuro 2013, Croatia, $70,000
    Danceact Seminar, Danceactive Estonia – Emotion in Motion!, Estonia, $75,600
    Education Foundation for Clinton City and Anderson County Schools, Inc., Making A Difference Through Community Gardens, United States, $25,000
    Education Foundation for Clinton City and Anderson County Schools, Get Moving!, United States, $25,000
    Epode International Network, Epode France, A Gold Standard Reference Obesity Prevention Programme, Belgium, $405,000
    Fort Worth Promotion and Development Fund, Fitworth, United States, $25,000
    Friends of the World Food Program, Inc., Project Thrive Colombia, Colombia, $72,746
    Gameday Healthy Kids Foundation, Healthy Kids Program, United States, $25,000
    Generation Europe Foundation, My Choices Planner, Belgium, $550,000
    Girls, Inc., Step It Up: Mind+Body Expansion, United States, $100,000
    Hollenbeck Police Activities League, Fit 4 Kids, United States, $25,000
    Horizons National Student Enrichment Program, Inc., Active Healthy Living Program, United States, $100,000
    Klichko Brothers Foundation, Call Your Friends – Let’s Play Together!, Ukraine, $200,000
    Los Angeles County Bicycle Coalition, Walk N’ Rollers’ Active Youth Engagement Program, United States, $25,000
    Miami Children’s Hospital Foundation, Healthy Chicas at Miami Childrens’ Hospital, United States, $25,000
    National 4-H Council, Youth Voice: Youth Council, United States, $250,000
    National Recreation and Park Association, Coca-Cola Troops for Fitness, United States, $3 million
    Olimpiady Specjalne Polska (Special Olympics), Active Lifestyles For All – Special Olympics, Poland, $30,000
    Polish Society of Dietetics, Wise Nutrition, Healthy Generation, Poland, $464,000
    Portland Parks Foundation, Healthy Active Communities Through Parks, United States, $25,000
    Recipe for Success, Seed-to-Plate Nutrition Education and Classroom Physical Activity, United States, $25,000
    San Antonio Food Bank, Mobilizing Health and Fitness Resources to Neighborhoods, United States, $300,000
    San Antonio Sports Foundation, Mobilizing Health and Fitness Resources to Neighborhoods, United States, $1.2 million
    Special Olympics Great Britain, 2013 National Summer Games, United Kingdom, $414,380
    Spelman College, Wellness Revolution, United States, $250,000
    Szkolny Zwiazek Sportowy (Sport School Association), Leader Sports Animators 2013, Poland, $272,000
    Think Detroit Police Athletic League, Inc., 2013 Soccer for Success, United States, $100,000
    Udruzenje Gradjana Delpas (Civil Association Delpas), Find the Right Measure, Serbia, $315,000
    United States Olympic Committee, U. S. Training Center in Colorado Springs: A Campaign for Excellence, United States, $250,000
    YMCA of Metropolitan Los Angeles, YMCA Play Program, United States, $25,000

PROTECTING THE ENVIRONMENT

Water

    Alternative Indigenous Development Foundation, Inc., Agos Crest Ram Pump Project, Philippines, $265,565
    Anacostia Watershed Society, Anacostia Watershed Environmental Education & Outdoor Recreation, United States, $25,000
    Coca-Cola Africa Foundation - Global Environment & Technology Foundation, Replenish Africa Initiative (RAIN), Africa, $6.7 million
    Europarc Deutschland E. V., Old Elbe Klieken - Restoration Of An Old River Oxbow, Germany, $390,000
    Earth Day Network Philippines, Inc., Agos Ram Pump Project, Philippines, $626,935
    Forest And Sea For Life Foundation, Enhancing The Capability Of Community Organizations And Klong Yan Watershed, Thailand, $139,355
    Lupin Human Welfare And Research Foundation, Integrated Watershed Area Development Approach For Dholpur District, Rajasthan, India, $351,568
    Pronatura México, A.C., Catch Water Ponds in Seven Communities in Mexico, Mexico, $600,000
    Shenzhen One Foundation Philanthropy Foundation, Clean Water Project, China, $557,000
    Umweltorganisation WWF International Danube-Carpathian Programme, Wetland Restoration In The Mura-Drava-Danube Area, Austria, $310,000
    United Nations Development Programme, Supplementary to the Ongoing Integrated Water Replenish Initiatives in China, China, $800,000
    Chattahoochee River Keeper, Keeping Our Waters and Citizens Healthy, United States, $25,000
    Fundacion Para La Sostenibilidad y la Equidad (Aliarse), The Water Vigilants Program 2013, Costa Rica, $60,000
    Korea Green Foundation, Rainwater Recycling Project, Korea, $50,000
    Pronatura Mexico AC, Cistern Network Program, Mexico, $80,000
    Raleigh International Trust, Clean Water for Communities, Malaysia, $48,442
    Sociedad Espanola De Ornitologia, Tancat de la Pipa – Natural Wastewater Treatment, Spain, $81,400

Recycling

    Bakersfield Arc, Program Development Material Recovery Facility, United States, $25,000
    Piedmont Park Conservancy, Recycling in Piedmont Park, United States, $20,000
    Städa Sverige/Pool2tusen, Clean Beaches And Water 2013, Sweden, $300,000

BUILDING STRONG COMMUNITIES

Education

    100 Black Men Of Atlanta, Inc., Project Success Program Continuation, United States, $50,000
    American Association of Community Colleges, New Century Scholarship Program, United States, $55,000
    Army Historical Foundation, The National Museum Of The United States Army/The Registry Of The American Soldier, United States, $1 million
    BGSU Foundation, Inc., Coca-Cola First Generation Scholarship Program, United States, $100,000
    Coca-Cola Africa Foundation, Zawadi Africa Educational Fund, Africa, $100,000
    Communities In Schools Of Georgia, CIS Network Empowerment Initiative, United States, $200,000
    Congressional Hispanic Caucus Institute, Inc., Fellows Program, United States, $100,000
    Hispanic Foundation of Silicon Valley, Parent Education Academy, United States, $50,000
    Intercultural Development Research Association, Coca-Cola Valued Youth Program, United States, $1 million
    Junior Achievement Of Georgia, Inc., JA Biztown And JA Finance Park, United States, $100,000
    KIPP Metro Atlanta Collaborative, KIPP Through College, United States, $50,000
    Maine Medical Center, Maine Medical Center Education Program, United States, $50,000
    National Coalition of 100 Black Women, Inc., Metropolitan Atlanta Chapter, Teens on the Move Scholarship Program, United States, $50,000
    Okefenokee Swamp Park, Okefenokee Swamp Education Programs, United States, $49,740
    Pronatura México, A.C., Strengthening Coca-Cola Environmental Education Activities In Mexico, Mexico, $160,000
    Regents Of The University Of California, Coca-Cola First Generation Scholarship Program, United States, $100,000
    Study Hall, Inc., The Study Hall, United States, $100,000
    Technical College System Of Georgia Foundation, Reducing Achievement Gaps & Increasing College Completion Rates, United States, $100,000
    Thorncliffe Neighborhood Office, Youth Success In School and Community, Canada, $50,000
    Thurgood Marshall College Fund, Coca-Cola First-Generation College Scholarships, United States, $150,000
    UNCF, Coca-Cola First Generation College Scholarships, United States, $350,000
    University Of Connecticut Foundation, Inc., Coca-Cola First Generation Scholarship Program, United States, $100,000

HIV/AIDS & Malaria

    Coca-Cola Africa Foundation - Christian Aid, The Isdell: Flowers Cross Border Malaria Initiative, United Kingdom, $500,000
    Coca-Cola Africa Foundation - Episcopal Relief & Development, Netsforlife, United States, $500,000
    Coca-Cola Africa Foundation - Hope Worldwide, Ltd., Care And Support For Orphans And Vulnerable Children In Africa, Africa, $400,000

Economic Development

    Chicago Urban League, Workforce Development: Success Strategies, United States, $50,000
    Milwaukee Urban League, Employment Assistance Program, United States, $25,000
    Pronatura México, A.C., Stevia Sustainability Use In Mexico, Mexico, $100,000

Youth Development

    Aga Khan Foundation USA, Empowering Youth For Socioeconomic Development, Eurasia and Africa, $250,000
    Drogheda Youth Development, Youth Empowerment for Drogheda’s Youth, Ireland, $25,900
    Philadelphia Youth Network, Inc., WorkReady Philadelphia 2013 Summer Internship Program, United States, $25,000
    Publisher’s Forum NGO, International Children’s Festival – Bookmania, Ukraine, $20,000
    Teammates Mentoring Program, Teammates Mentoring Program, United States, $25,000

Civic Initiatives

    National Black Arts Festival, Education and Public Programs, United States, $50,000
    National Underground Railroad Freedom Center, Museum Science Apprenticeship Program, United States, $100,000.
    Blue Star Families, Capacity Building and Infrastructure Improvement, United States, $50,000
    Reconcile New Orleans, Creating Pathways to Health and Self Sufficiency, United States, $25,000
    Atlanta Police Foundation, Inc., The Public Safety: Next Generation Campaign, United States, $300,000
    Pronatura Mexico AC, Forest Nursery Training in Mexico, Mexico, $20,000
    Tampa Bay Watch, McKay Bay Oyster Reef Creation and Enhancement Project, United States, $25,000
    Victor Pinchuk Foundation, Zavtra Ua Summer Green Camp, Ukraine, $50,000
    Pronatura México, A.C., Oregano Sustainability Use In Central Mexico, Mexico, $100,000
    Pronatura México, A.C., A Silvicultural Model Development In Mexico, Mexico, $150,000
    Coca-Cola Africa Foundation - Citihope International Inc., The 2013 Sharehope Program, United States, $700,000
    Coca-Cola Africa Foundation - Medshare International Inc., The Sharehope, Eurasia & Africa, $800,000

About The Coca-Cola Foundation

The Coca-Cola Foundation has awarded more than $500 million to support global sustainable community initiatives, including water stewardship, community recycling, active healthy living, and education. For more information about The Coca-Cola Foundation, please go to http://www.coca-colacompany.com/our-company/the-coca-cola-foundation.

About The Coca-Cola Company

The Coca-Cola Company (NYSE: KO) is the world's largest beverage company, refreshing consumers with more than 500 sparkling and still brands. Led by Coca-Cola, the world's most valuable brand, our Company's portfolio features 16 billion-dollar brands including Diet Coke, Fanta, Sprite, Coca-Cola Zero, vitaminwater, Powerade, Minute Maid, Simply, Georgia and Del Valle. Globally, we are the No. 1 provider of sparkling beverages, ready-to-drink coffees, and juices and juice drinks. Through the world's largest beverage distribution system, consumers in more than 200 countries enjoy our beverages at a rate of more than 1.8 billion servings a day. With an enduring commitment to building sustainable communities, our Company is focused on initiatives that reduce our environmental footprint, support active, healthy living, create a safe, inclusive work environment for our associates, and enhance the economic development of the communities where we operate. Together with our bottling partners, we rank among the world's top 10 private employers with more than 700,000 system associates. For more information, visit Coca-Cola Journey at www.coca-colacompany.com, follow us on Twitter at twitter.com/CocaColaCo or check out our blog, Coca-Cola Unbottled, at www.coca-colablog.com.

Contacts

The Coca-Cola Foundation

Wanda Yancey Rodwell, +01 404.676.2683

Global Community Connections

wrodwell@coca-cola.com









Permalink: http://www.me-newswire.net/news/7734/en

New efficacy and safety data presented for Trajenta® (linagliptin) in Asians with Type 2 Diabetes

New Phase III data presented at the American Diabetes Association 73rd Scientific Sessions® (ADA) showed linagliptin improved blood glucose control as monotherapy and in combination with metformin, in Asian people from China, Malaysia and the Philippines with Type 2 Diabetes.

INGELHEIM, Germany & INDIANAPOLIS, US - Saturday, June 22nd 2013 [ME NewsWire]

(BUSINESS WIRE)-- For Non-US and Non-UK Media

Boehringer Ingelheim and Eli Lilly and Company today presented results from two randomised Phase III clinical trials evaluating the efficacy and safety of linagliptin in Asians from China, Malaysia and the Philippines with Type 2 Diabetes (T2D). The results showed that adults with T2D treated with linagliptin both as monotherapy and in combination with metformin achieved improved blood glucose control compared with placebo.

The rate of Type 2 Diabetes is rapidly increasing in Asia with the present trend indicating that more than 60% of the world’s diabetic population will be in Asia by 2030.1

“People with Type 2 Diabetes in Asia tend to develop diabetes at a younger age when compared to people in other regions,” said Professor Guang Ning, Director and Professor of the Department of Endocrine and Metabolism, Shanghai Ruijin Hospital, China. “Therefore they tend to suffer longer with the complications of Type 2 Diabetes and have a lower life expectancy compared with people with diabetes from other regions. It is becoming increasingly important to find effective, safe and well tolerated treatments for Asian patients with Type 2 Diabetes. The results of these two trials have shown that linagliptin could become an important option for these patients.”

Results of the first Phase III study, evaluating the efficacy and safety of linagliptin monotherapy in Asians from China, Malaysia and the Philippines with T2D showed that linagliptin demonstrated a 0.68% reduction in HbA1c at 24 weeks versus a reduction of 0.18% in the placebo group (baseline HbA1c 8.09%, p<0.0001). Results for the pre-defined Chinese subgroup were similar to the overall population and the subgroup of patients with baseline HbA1c ≥8.5%, the placebo-corrected decrease in HbA1c from baseline at 24 weeks was −0.91% (P<0.0001).2 HbA1c is measured in people with diabetes to provide an index of blood glucose control for the previous two to three months.3

Results from the second Phase III study evaluating the efficacy and safety of linagliptin added to metformin in Asians from China, Malaysia and The Philippines with T2D found that patients randomised to the linagliptin plus metformin arm achieved a HbA1c reduction of 0.66% versus 0.14% in the placebo group (p<0.0001).

In both studies, linagliptin was well tolerated. In the first study, adverse events (AEs) occurred in 28.0% of linagliptin patients and 28.3% of placebo patients, while drug-related AEs occurred in 3.0% of linagliptin patients and 2.0% of placebo patients. In the second study, AEs occurred in a similar proportion of patients as in the placebo group (27.3% and 28.0%, respectively). Drug-related AEs were reported for 2.4% and 0.0% of linagliptin and placebo patients, respectively. Investigator-defined hypoglycemia occurred in 0.5% and 0.0% of linagliptin and placebo treated patients respectively, in the first study and 1.0% in both groups in the second study.2,3 The primary endpoint of both studies was change from baseline in mean HbA1c after 24 weeks.2,3

The US Food and Drug Administration (FDA), European Medicines Agency (EMA) and other regulatory authorities worldwide approved linagliptin for the treatment of adult patients with T2D as monotherapy or in combination with metformin/metformin plus sulphonylurea, and as add-on therapy to insulin.4 Linagliptin received approval in China in March 2013. With linagliptin, no dose adjustment is required regardless of declining renal function or hepatic impairment.4,5

About the Phase III studies

Efficacy and safety of linagliptin monotherapy in Asian patients with inadequately controlled Type 2 Diabetes mellitus: a 24 week, randomized, Phase III clinical trial: 1218.66

This randomised, Phase III, placebo-controlled, double-blind 24-week study evaluated the efficacy and safety of the DPP-4 inhibitor linagliptin as monotherapy in patients with inadequately controlled T2D in three Asian countries. Patients who were treatment naïve or who had been treated with one antihyperglycemic drug were randomised to either linagliptin 5 mg daily or placebo following 4-week washout of prior drugs. The primary endpoint was change from baseline in mean HbA1c after 24 weeks. The study included a total of 300 Asian patients (China n=261, Malaysia n=22 and the Philippines n=17) with T2D.

Efficacy and safety of linagliptin in Asian patients with Type 2 Diabetes mellitus inadequately controlled on metformin: a 24 week, randomized, Phase III clinical trial: 1218.65

This randomised, Phase III, placebo controlled, double blind 24 week study evaluated the efficacy and safety of linagliptin added to metformin in Asian people with T2D. Antihyperglycemic drugs other than metformin were washed out for 4 weeks prior to randomization to either linagliptin 5mg daily or placebo added to metformin. The primary endpoint of the study was change from baseline in mean HbA1c after 24 weeks.

The study included a total of 306 Asian patients (China n=265, Malaysia n=17 and the Philippines n=24) with T2D.

About Linagliptin

Linagliptin (5 mg, once daily) is marketed in Europe as Trajenta® (linagliptin) and in the U.S. as Tradjenta® (linagliptin), as a once-daily tablet that is used along with diet and exercise to improve glycaemic control in adults with T2D. Linagliptin should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis (increased ketones in the blood or urine). With linagliptin, no dose adjustment is required regardless of declining renal function or hepatic impairment.4,5 Linagliptin is also approved in combination with metformin in Europe and the US, under the trade name Jentadueto®. Jentadueto® is approved as a twice-daily tablet that is used along with diet and exercise to improve glycaemic control in adults with T2D, who are inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of linagliptin and metformin.

~ENDS~

Please click on the link below for ‘Notes to Editors’ and ‘References’: http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2013/22_june_2013_linagliptin1.html

Contacts

Dr. Ralph Warsinsky

Corporate Communications

Boehringer Ingelheim GmbH

Email: press@boehringer-ingelheim.com

Phone: +49 178 290 8561



or

Tammy Hull

Communications Manager

Lilly Diabetes

Email: hullta@lilly.com

Phone: +1 (317) 651 9116






Phase III data show investigational compound empagliflozin reduced blood glucose in adults with Type 2 Diabetes treated with basal insulin

Data presented at the American Diabetes Association 73rd Scientific Sessions® also showed reduction in required insulin dose in treated study subjects

INGELHEIM, Germany & Indianapolis, US - Saturday, June 22nd 2013 [ME NewsWire]

(BUSINESS WIRE/ME NewsWire)-- For Non-US and Non-UK Media

Boehringer Ingelheim and Eli Lilly and Company today announced results of a 78-week Phase III clinical trial of the investigational compound empagliflozin* as an add-on to basal insulin in people with Type 2 Diabetes (T2D). The study, presented at the American Diabetes Association (ADA) 73rd Scientific Sessions®, showed that empagliflozin 10mg and 25mg, produced statistically significant reductions in HbA1c (average blood glucose), compared to placebo as add-on to basal insulin, at the time of assessment Data presented at the American Diabetes Association 73rd Scientific Sessions® also showed reduction in required insulin dose in treated study subjects

of the study’s primary endpoint, week 18, as well as at week 78.1

Empagliflozin is a member of the sodium glucose cotransporter 2 (SGLT2) inhibitor class of drugs and is being investigated for the reduction of blood glucose levels in adults with T2D. The emerging SGLT2 inhibitor class removes excess glucose through the urine by reducing glucose reabsorption in the kidney.

“This study is an important component of the clinical programme of the Boehringer Ingelheim and Lilly Diabetes alliance, which is designed to examine empagliflozin as an add-on therapy to a broad range of existing treatments for people with Type 2 Diabetes,” said Professor Klaus Dugi, Corporate Senior Vice President Medicine, Boehringer Ingelheim. “The results observed in this study are encouraging as empagliflozin in combination with basal insulin demonstrated significant improvements in glucose control as well as weight loss”.

The study included an 18-week fixed insulin dose period, after which the dose was adjusted at investigator discretion.1 Results of the study with empagliflozin as an add-on to basal insulin in people with T2D included:

    At week 18, placebo-adjusted reductions in HbA1c for empagliflozin 10mg and 25mg of 0.6% and 0.7% (p<0.001), respectively.1
    Confirmed hypoglycaemia (glucose ≤70mg/dL and/or requiring assistance) was reported in 20%, 28% and 21% of patients on empagliflozin 10mg, 25mg and placebo respectively, at week 18.
    At week 78, placebo-adjusted reductions in HbA1c for empagliflozin 10mg and 25mg of 0.5% and 0.6% (p<0.001), respectively. Daily insulin dose was changed from baseline by -1.2IU, -0.5IU and 5.5IU for empagliflozin 10mg, 25mg and placebo, respectively.1
    Both empagliflozin doses and placebo had comparable confirmed hypoglycaemic events (glucose ≤70mg/dL and/or requiring assistance); 36% reported by patients on both empagliflozin 10mg and 25mg, and 35% on placebo, at week 78.

Adverse events were reported by 85% and 87% of patients on empagliflozin 10mg and 25mg, respectively and by 87% of patients on placebo at week 78. Common adverse events included hypoglycaemia (see rates detailed above - 2 patients on empagliflozin 25mg required assistance), as well as adverse events consistent with urinary tract infection (reported in 15%, 12% and 9% of patients on empagliflozin 10mg, 25mg and placebo, respectively) and genital infection (reported in 8%, 5% and 2% of patients on empagliflozin 10mg, 25mg and placebo, respectively).

Further analysis also showed at week 78:

    A statistically significant reduction in body weight of 2.2kg (p<0.001) and 2.0kg (p<0.001) for empagliflozin 10mg and 25mg, respectively, compared to an increase of 0.7kg for placebo1.
    Changes in systolic blood pressure were statistically significant in the empagliflozin 10mg group [-4.1mmHg (p=0.004)] but not in the empagliflozin 25mg group [-2.4mmHg (p=0.099)], compared to placebo [0.1mmHg].1

About the study

The 78-week, randomised, double-blind placebo-controlled trial investigated the safety and efficacy of empagliflozin as an add-on to basal insulin in people with T2D. Patients were randomised to receive empagliflozin 10mg (n=169), empagliflozin 25mg (n=155) or placebo (n=170). Basal insulin dose remained constant for the first 18 weeks. Thereafter, adjustments were allowed at investigator discretion. Primary endpoint was change from baseline in HbA1c at week 18. Key secondary endpoints were changes from baseline in insulin dose and HbA1c at week 78.1

About the empagliflozin Phase III clinical trial programme

Empagliflozin is being investigated in adults with T2D in a Phase III clinical trial programme that plans to enrol more than 14,500 patients. This programme comprises more than 10 multinational clinical trials, including a large cardiovascular outcomes trial.

*Empagliflozin is an investigational compound. Its safety and efficacy have not been established.

~ENDS~

Please click on the link below for ‘Notes to Editors’ and ‘References’: http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2013/22_june_2013_empagliflozin2.html

Contacts

Boehringer Ingelheim GmbH

Marco Winkler

Product Communication Manager

Email: press@boehringer-ingelheim.com

Phone: +49 (151) 689 46812



or

Lilly Diabetes

Tammy Hull

Communications Manager

Email: hullta@lilly.com

Phone: +1 (317) 651 9116

Permalink: http://me-newswire.net/news/7737/en

Study finds investigational compound empagliflozin reduced blood glucose in adults with Type 2 Diabetes and impaired kidney function

Data presented at American Diabetes Association 73rd Scientific Sessions® also showed reductions in weight and blood pressure


INGELHEIM, Germany & INDIANAPOLIS, US - Saturday, June 22nd 2013 [ME NewsWire]

(BUSINESS WIRE)-- For Non-US and Non-UK Media

Boehringer Ingelheim and Eli Lilly and Company today announced results of a 52-week Phase III clinical trial of the investigational compound empagliflozin*, which showed statistically significant reductions in HbA1c (average blood glucose) at week 24, with the addition of empagliflozin to existing oral glucose-lowering therapy in people with Type 2 Diabetes (T2D) and mild to moderate renal impairment as measured by the estimated glomerular filtration rate (eGFR ≥60 to <90mL/min/1.73m2 and eGFR ≥30 to <60mL/min/1.73 m2).1

Empagliflozin is a member of the sodium glucose cotransporter 2 (SGLT2) inhibitor class of drugs and is being investigated for the reduction of blood glucose levels in adults with T2D. The emerging SGLT2 inhibitor class removes excess glucose through the urine by reducing glucose reabsorption in the kidney.

Results from the study, presented at the American Diabetes Association (ADA) 73rd Scientific Sessions®, also demonstrated a significant reduction in body weight and significant improvements in blood pressure with empagliflozin versus placebo in patients with mild to moderate renal impairment.1

“Today, nearly half of all new cases of kidney failure are due to diabetes. The Boehringer Ingelheim and Lilly Diabetes alliance is using its collective knowledge to find new treatment options that meet the different needs of people with diabetes,” said Professor Klaus Dugi, Corporate Senior Vice President Medicine, Boehringer Ingelheim. “This data demonstrated the potential for empagliflozin in people with Type 2 Diabetes, including people with renal impairment”.

At week 24, results of the study with empagliflozin in patients with renal impairment included:

    Placebo-adjusted reductions in HbA1c of 0.52% (p<0.001) and 0.68% (p<0.001) for empagliflozin 10mg and 25mg, respectively, in patients with mild renal impairment; for empagliflozin 25mg, placebo-adjusted reductions in HbA1c of 0.42% (p<0.001) in patients with moderate renal impairment1
    Decrease in fasting plasma glucose (FPG) levels in patients with mild renal impairment of 13.88 mg/dL (p<0.001) and 18.08mg/dL (p<0.001) for empagliflozin 10mg and 25mg, respectively, and an increase of 5.67mg/dL for placebo; in patients with moderate renal impairment, a decrease in FPG levels of 9.26mg/dL (p<0.001) for empagliflozin 25mg and an increase of 10.16mg/dL for placebo1
    Loss of 1.76kg (p<0.001) and 2.33kg (p<0.001) of body weight in patients with mild renal impairment for empagliflozin 10mg and 25mg, respectively, compared with a loss of 0.33kg for placebo; loss of 0.98kg (p<0.001) in body weight in patients with moderate renal impairment for empagliflozin 25mg, compared with a loss of 0.08kg for placebo1
    Improvements in both systolic (SBP) and diastolic blood pressure (DBP) with empagliflozin versus placebo:
        SBP decreased in patients with mild renal impairment by 2.9mmHg (p=0.033) and 4.5mmHg (p=0.002) for empagliflozin 10mg and 25mg, respectively, while it increased by 0.7mmHg for placebo; SBP decreased in patients with moderate renal impairment by 3.9mmHg (p=0.001) for empagliflozin 25mg, and increased by 0.4mmHg for placebo1
        DBP decreased in patients with mild renal impairment by 1.4mmHg (p=0.006) and 2.2mmHg (p<0.001) for empagliflozin 10mg and 25mg, respectively, while it increased by 1.1mmHg for placebo; DBP decreased in patients with moderate renal impairment by 1.7mmHg (p=0.020) for empagliflozin 25mg, and increased by 0.2mmHg for placebo.1

In this study group of people with T2D and mild or moderate renal impairment, the percentage of people who reported adverse events at 24 weeks were: 79.6%, 75.4% and 72.7% on empagliflozin 10mg, 25mg and placebo, respectively. Common adverse events include hypoglycaemia (plasma glucose ≤70mg/dL and/ or requiring assistance – reported in 23.5% of patients on empagliflozin 10mg, 22.1% on empagliflozin 25mg and 22.9% on placebo), as well as adverse events consistent with urinary tract infection (reported in 10.2% of patients on empagliflozin 10mg, 9.0% on empagliflozin 25mg and 8.2% on placebo) and genital infection (reported in 6.1% of patients on empagliflozin 10mg, 2.5% on empagliflozin 25mg and 1.3% on placebo).

At 52 weeks, results of the study showed placebo-adjusted reductions in HbA1c of 0.62% (p<0.001) and 0.65% (p<0.001) for empagliflozin 10mg and 25mg, respectively, in patients with mild renal impairment. In patients with moderate renal impairment, results at 52 weeks showed placebo-adjusted reductions in HbA1c of 0.44% (p<0.001) for empagliflozin 25mg. Across all randomised groups at 52 weeks, adverse events were reported by 87.8% and 83.5% of patients on empagliflozin 10mg and 25mg respectively, and 84.6% on placebo.

About the study

The 52-week randomised, double-blind, placebo-controlled trial investigated the safety and efficacy of empagliflozin as an add-on to existing therapy in people with T2D and renal impairment.1 The primary endpoint was change from baseline in HbA1c at week 24. Exploratory endpoints included changes from baseline in FPG, weight and blood pressure at week 24.1

About the empagliflozin Phase III clinical trial programme

Empagliflozin is being investigated in adults with T2D in a Phase III clinical trial programme that plans to enrol more than 14,500 people. This programme comprises more than 10 multinational clinical trials, including a large cardiovascular outcomes trial.

*Empagliflozin is an investigational compound. Its safety and efficacy have not been established.

~ENDS~

Please click on the link below for ‘Notes to Editors’ and ‘References’: http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2013/22_june_2013_empagliflozin1.html

Contacts

Boehringer Ingelheim GmbH

Marco Winkler

Product Communication Manager

Email: press@boehringer-ingelheim.com

Phone: +49 (151) 689 46812



or

Lilly Diabetes

Tammy Hull

Communications Manager

Email: hullta@lilly.com

Phone: +1 (317) 651 9116







Permalink: http://me-newswire.net/news/7740/en

Toshiba Launches New MOSFET "SSM3K337R" for Relay Drivers

Active clamp structure prevents overvoltage when inductive load is switched off

TOKYO - Saturday, June 22nd 2013 [ME NewsWire]

(BUSINESS WIRE)-- Toshiba Corporation (TOKYO: 6502) today announced that it has launched a MOSFET, "SSM3K337R", for relay drivers. The new device uses an active clamp structure that prevents overvoltage when the inductive load of relay devices is switched off. Sample is available and mass production is scheduled to start in September. Demand for relay drivers is growing for automobile, since the number of electric components equipped by automobile is increasing. The "SSM3K337R" reduces ON-resistance by half and improves allowable power dissipation to approximately 1.6 times that of equivalent products.


Key Features

1.
         

Active clamp structure reduces stress by inductive load of relay devices.

2.
         

ON-resistance is reduced by half.

3.
         

Allowable power dissipation is improved to approximately 1.6 times, with SOT-23F package.


Main Specifications

For more information about the product, please see the product page. http://www.semicon.toshiba.co.jp/eng/product/new_products/transistor/1323380_37649.html

Customer Inquiries: Small Signal Device Sales and Marketing Department Tel: +81-3-3457-3411


Information in this document, including product prices and specifications, content of services and contact information, is current on the date of the announcement but is subject to change without prior notice.


About Toshiba

Toshiba is a world-leading diversified manufacturer, solutions provider and marketer of advanced electronic and electrical products and systems. Toshiba Group brings innovation and imagination to a wide range of businesses: digital products, including LCD TVs, notebook PCs, retail solutions and MFPs; electronic devices, including semiconductors, storage products and materials; industrial and social infrastructure systems, including power generation systems, smart community solutions, medical systems and escalators & elevators; and home appliances.

Toshiba was founded in 1875, and today operates a global network of more than 550 consolidated companies, with 202,000 employees worldwide and annual sales surpassing 6.1 trillion yen (US$74 billion). Visit Toshiba's web site at www.toshiba.co.jp/index.htm

To view the full press release please click here

Photos/Multimedia Gallery Available:  http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50657332&lang=en

Contacts

Media Inquiries:

Toshiba Corporation

Semiconductor & Storage Products Company

Takashi Mochizuki, +81-3-3457-4963

semicon-NR-mailbox@ml.toshiba.co.jp

 

CLOTS 3 Study Delivers Lifesaving Results Using Covidien’s Blood Clot Prevention Technology

Study Shows Sequential Compression Sleeves Reduce DVT Events in Immobile Stroke Patients

MANSFIELD, Mass. - Saturday, June 22nd 2013 [ME NewsWire]

(BUSINESS WIRE)-- Covidien (NYSE: COV), a leading global provider of healthcare products, today announced that an independent study conducted by the University of Edinburgh has successfully demonstrated the effectiveness of Covidien’s Kendall SCD™ system with Vascular Refill Detection Technology on immobile stroke patients.

The results of the CLOTS 3 trial were presented at the European Stroke Conference by Professor Martin S. Dennis of the University of Edinburgh’s Division of Clinical Neurosciences and also published in The Lancet. The new study showed a 29.9% decrease in the development of proximal deep vein thrombosis (DVT) in immobile stroke patients who received intermittent pneumatic compression (IPC) using the Kendall SCD system with Vascular Refill Detection Technology, which delivers sequential, circumferential, gradient compression through thigh-length sleeves. Compared to the routine care group only, the IPC group also showed a 14% mortality risk reduction (p = 0.042) during the first six months after hospital admission for stroke.

“At last we have a simple, safe and affordable treatment that reduces the risk of DVT and even appears to reduce the risk of dying after a stroke,” said Prof. Dennis. “We estimate that this treatment could potentially help about 400,000 stroke patients each year in the U.S. If this number were treated, we would prevent about 20,000 patients from developing a DVT and perhaps save 10,000 lives.

“We believe that the national guidelines need to be revised in the light of our findings,” added Prof. Dennis. “The current guidelines have suggested that IPC should be considered only where blood thinning injections are unsuccessful or inappropriate, but this research suggests that IPC should be used in all patients at high risk of DVT.”

“The results from the CLOTS 3 study are truly groundbreaking, “ said Mark A. Turco, MD, Chief Medical Officer, Vascular Therapies, Covidien. “The large, statistically significant mortality reduction in stroke patients treated with sequential compression versus routine care, as well as the near 30% reduction in proximal DVT, should revolutionize post-stroke treatment leading to improved patient outcomes.”

About the CLOTS 3 Trial

The largest trial of its kind, CLOTS 3 was a multicenter, randomized, controlled study that evaluated the effectiveness of IPC in reducing the risk of DVT and death in stroke patients. The study enrolled 2,876 patients between 2008 and 2012, and involved 105 hospitals in the United Kingdom. The trial was funded by the National Institute of Health, the Health Technology Assessment program and the Chief Scientist Office Scotland. Covidien donated the Kendall SCD compression systems to participating hospitals.

About Deep Vein Thrombosis and Intermittent Pneumatic Compression

DVTs are blood clots that can form in the leg, travel to the lungs and cause death. Current methods to prevent DVT include medicines that thin the blood. However, these medications often carry an increased risk of bleeding, which can be a serious drawback for stroke patients. Blood thinning agents have not been conclusively shown to reduce the risk of dying after stroke1.

IPC is a medical device that squeezes the leg gently to increase blood flow and is proven to decrease the risk of DVT2. This is especially important in patients who are immobile, such as patients who suffer from acute stroke.

    Lederle FA, Zylla D, MacDonald R, Wilt TJ. Venous thromboembolism prophylaxis in hospitalized medical patients and those with stroke: a background review for an American College of Physicians Clinical Practice Guideline. Ann Intern Med. 2011 Nov 1;155(9):602-15.
    Collen JF, Jackson JL, Shorr AF, Moores LK. Prevention of venous thromboembolism in neurosurgery: a metaanalysis. Chest. 2008 Aug;134(2):237-49

About Covidien

Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines in three segments: Medical Devices, Pharmaceuticals and Medical Supplies. With 2012 revenue of $11.9 billion, Covidien has 43,000 employees worldwide in 70 countries, and its products are sold in over 140 countries. Please visit www.covidien.com to learn more about our business.

Contacts

Covidien

David T. Young, 508-452-1644

Manager, External Communications

Vascular Therapies

david.young@covidien.com



Bruce Farmer, 508-452-4372

Vice President

Public Relations

bruce.farmer@covidien.com



Coleman Lannum, CFA, 508-452-4343

Vice President

Investor Relations

cole.lannum@covidien.com



Todd Carpenter, 508-452-4363

Senior Director

Investor Relations

todd.carpenter@covidien.com



Permalink: http://www.me-newswire.net/news/7732/en